来自非热气等离子体 (CAP) 的反应性氧物种:对向癌症干细胞的含义
Amirhesam Babajani1, Afshin Eftekharinasab2, Sander Bekeschus3
1Oncopathology Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Cancer cell international
|October 23, 2024
概括
非热气等离子体 (CAP) 通过向癌症干细胞 (CSCs) 显示出对癌症治疗的希望. 这种创新方法利用活性氧物种 (ROS) 选择性地消除CSC,可能克服治疗耐药性和复发.
科学领域:
- 在瘤学瘤学.
- 生物物理学的生物物理.
- 生物医学工程 生物医学工程
背景情况:
- 癌症干细胞 (CSCs) 驱动治疗耐药性和复发,在瘤学中构成重大挑战.
- 目前的癌症疗法往往难以有效准和消除CSC.
- 非热气等离子体 (CAP) 是一种新兴的治疗方式,具有选择性,免疫性和强大的抗癌性质.
研究的目的:
- 审查CAP作为向癌症干细胞 (CSCs) 的治疗策略的潜力.
- 探索CAP调节细胞状态并实现CSCs中氧化还原平衡的能力.
- 通过了解CSC属性和CAP的有效性,提供对创新的瘤学策略的见解.
主要方法:
- 对癌症干细胞 (CSC) 和非热气体等离子体 (CAP) 应用现有文献的审查.
- 分析CAP的组成,重点关注活性氧物种 (ROS) 和它们在治疗效果中的作用.
- 评估关于CAP对民间社会危害的有效性及其作用机制的最新发现.
主要成果:
- CAP具有选择性,免疫性和强大的抗癌性质,主要归因于活性氧物种 (ROS).
- 来自CAP的ROS的动态相互作用影响生物系统并引起治疗效应.
- 虽然在各种癌症中很有希望,但CAP对CSC的应用仍然相对未被探索,但显示出潜力.
结论:
- 作为一种针对癌症干细胞 (CSCs) 的有希望的创新策略,CAP代表着一个有希望的创新策略.
- 了解CAP衍生的ROS和CSC之间的相互作用对于开发有效的癌症疗法至关重要.
- 对CAP对CSC的疗效进行进一步的研究可能会导致先进的瘤治疗方法.
相关概念视频
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Electron Transport Chain: Complex I and II
12.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.0K


